Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 1:08 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2737–2760 of 14,150 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Safety Control Clear all

Conditions: Non Alcoholic Steatohepatitis (NASH)
Interventions: Obeticholic Acid, Placebo; Drug
Lead sponsor: Intercept Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 2,477 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 175
States / cities: Birmingham, Alabama • Dothan, Alabama • Chandler, Arizona + 116 more

Conditions: Depressive Disorder, Treatment-Resistant
Interventions: AVP-786 (d6-dextromethorphan hydrobromide and quinidine sulfate combination), Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 32
States / cities: Birmingham, Alabama • Bellflower, California • Costa Mesa, California + 26 more

Conditions: Rheumatoid Arthritis
Interventions: IDEC-C2B8 (rituximab), Placebo, Methotrexate, Etanercept, Adalimumab, Methylprednisolone, Folate; Biological · Drug · Dietary Supplement
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 18
States / cities: Huntsville, Alabama • Paradise Valley, Arizona • Palm Desert, California + 15 more

Conditions: Healthy Volunteers
Interventions: TAK-058, TAK-058 Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Austsitn, Texas

Conditions: Systemic Lupus Erythematosus
Interventions: Epratuzumab, Placebo; Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 793 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 50
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Escondido, California + 41 more

Conditions: Pandemic Influenza Immunization, Healthy Volunteers
Interventions: Pandemic flu H5 HA mRNA SD2 vaccine, Placebo; Biological · Other
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 720 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 13
States / cities: La Mesa, California • DeLand, Florida • Lakeland, Florida + 10 more

Conditions: Multiple Myeloma
Interventions: JCARH125, JCARH125 + anakinra; Biological
Lead sponsor: Juno Therapeutics, a Subsidiary of Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 20
States / cities: Birmingham, Alabama • Duarte, California • Los Angeles, California + 16 more

Conditions: In-hospital Cardiac Arrest, Cardiopulmonary Resuscitation
Interventions: SAMURAI PICU Bundle; Other
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: Not listed
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 5
States / cities: Chicago, Illinois • Akron, Ohio • Charleston, South Carolina + 2 more

Conditions: Interstitial Cystitis, Bladder Pain Syndrome
Interventions: SI-722, Placebo; Drug
Lead sponsor: Seikagaku Corporation; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 5
States / cities: Los Angeles, California • Murrieta, California • The Villages, Florida + 2 more

Conditions: Rotator Cuff Tears, Shoulder Injuries, Hallux Valgus, Ankle Arthropathy, Clavicle Fracture
Interventions: Experimental Treatment, Sham Comparator; Device
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Knee Osteoarthritis
Interventions: iovera°, Sham Comparator; Device
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 35 Years to 75 Years
Enrollment: 180 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 17
States / cities: Covina, California • Sacramento, California • Bradenton, Florida + 14 more

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Reldesemtiv, Placebo; Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 489 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 36
States / cities: Phoenix, Arizona • Los Angeles, California • Orange, California + 30 more

Conditions: Crohn Disease
Interventions: Sargramostim (Leukine), Placebo; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 47
States / cities: Huntsville, Alabama • Orange, California • San Francisco, California + 43 more

Conditions: Dry Eye Disease
Interventions: SI-614, Placebo; Drug
Lead sponsor: Seikagaku Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 232 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 6
States / cities: Newport Beach, California • Louisville, Kentucky • Andover, Massachusetts + 3 more

Conditions: Corneal Abrasion
Interventions: Ophthalmic Tetracaine, Normal Saline; Drug · Other
Lead sponsor: New York Presbyterian Brooklyn Methodist Hospital; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Dry Eye
Interventions: IVW-1001 Ophthalmic Eyelid Wipe 0.2%, IVW-1001 Ophthalmic Eyelid Wipe 0.4%; Drug
Lead sponsor: IVIEW Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Mucositis, Nephrotoxicity, Ototoxicity
Interventions: Tempol, Placebo Solution; Drug
Lead sponsor: Matrix Biomed, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 9
States / cities: La Jolla, California • Merced, California • San Francisco, California + 4 more

Conditions: Crohn's Disease
Interventions: Guselkumab, Golimumab, JNJ-78934804, Placebo; Biological · Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 703 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 90
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 79 more

Conditions: Diabetes, Diabetes Mellitus, Type 1
Interventions: liraglutide, placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 4
States / cities: Duarte, California • Chicago, Illinois • Boston, Massachusetts + 1 more

Conditions: Diabetic Peripheral Neuropathy, Pain
Interventions: Capsaicin 8%, Placebo; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older
Enrollment: 369 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 29
States / cities: Anniston, Alabama • Fresno, California • Long Beach, California + 24 more

Conditions: Parkinson Disease
Interventions: DNL201, Placebo; Drug
Lead sponsor: Denali Therapeutics Inc.; Industry
Eligibility: 30 Years to 80 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 7
States / cities: Long Beach, California • Aurora, Colorado • Miami, Florida + 4 more

Conditions: Parkinson's Disease
Interventions: Istradefylline (KW-6002); Drug
Lead sponsor: Kyowa Kirin, Inc.; Industry
Eligibility: 30 Years and older
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Princeton, New Jersey

Conditions: Crohn's Disease
Interventions: Prochymal®, Placebo; Drug
Lead sponsor: Mesoblast, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 47
States / cities: Los Angeles, California • San Francisco, California • Wheat Ridge, Colorado + 38 more

Conditions: Acute Kidney Injury
Interventions: ANG-3777, Placebo; Drug
Lead sponsor: Angion Biomedica Corp; Industry
Eligibility: 18 Years and older
Enrollment: 275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 23
States / cities: Los Angeles, California • Palo Alto, California • San Diego, California + 18 more

Search by objective public record fields.

Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment

Efficacy, Safety, and Tolerability Study of AVP-786 as an Adjunctive Therapy in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment

Safety and Tolerability of Rituxan With Methotrexate and Etanercept or Methotrexate and Adalimumab in Patients With Active Rheumatoid Arthritis

Safety, Tolerability, and Pharmacokinetics of Multiple-Dose TAK-058 in Healthy Participants

Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus

Study to Evaluate the Safety and the Immunogenicity of a Second Generation Structurally Designed mRNA Vaccine Candidate Against Pandemic Influenza H5 HA Strain in Healthy Adult Participants Aged 18 Years and Older

Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myeloma

Situation Awareness Incorporating Multidisciplinary Teams Reduce Arrests In the Pediatric ICU

PK and Safety of SI-722 in IC/BPS

Randomized Study of an Analgesic Device Enabling Local Anesthetic Delivery and Neuromodulation After Shoulder/Foot Surgery

Study to Evaluate the Iovera° Device for Temporary Relief From Knee Pain

A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)

Efficacy (Induction of Response/Remission) and Safety Study in Patients With Moderate to Severe Crohn's Disease

A Study for Evaluation of the Efficacy and Safety of SI-614 Ophthalmic Solution in Patient With Dry Eye

Treatment of Corneal Abrasions With Topical Tetracaine

Phase 2b Controlled Study of Dosing Techniques - Part B

Treatment of Radiation and Cisplatin Induced Toxicities with Tempol

A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease

Efficacy and Safety of Liraglutide in Subjects With Type 1 Diabetes Undergoing Islet Cell Transplantation

A Study to Evaluate Efficacy and Safety of a Single Application of Capsaicin 8%Transdermal Delivery System Compared to Placebo in Reducing Pain Intensity in Subjects With Painful Diabetic Peripheral Neuropathy (PDPN)

Study to Evaluate DNL201 in Subjects With Parkinson's Disease

A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa

Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

Study to Prevent Acute Kidney Injury After Cardiac Surgery Involving Cardiopulmonary Bypass